DTx in Pediatric Care: ADHD, Autism Spectrum Disorder, and Obesity
Pediatric populations present unique therapeutic needs—and Digital Therapeutics are rising to the occasion by offering non-invasive, scalable solutions for conditions like ADHD, autism spectrum disorder (ASD), and childhood obesity.
In 2020, the FDA made headlines by approving EndeavorRx®, the first game-based DTx for pediatric ADHD. Designed to improve attention function, the software is prescribed for children aged 8–12 and delivers therapy through a mobile game. Clinical trials showed improvements in attention scores comparable to pharmacologic interventions—without the same side effect profiles.
For children with ASD, DTx programs focus on social skill development, language therapy, and behavioral tracking. These platforms allow caregivers and therapists to monitor interactions and progress remotely, offering continuity of care between sessions and in underserved areas.
Childhood obesity-focused DTx tools use gamified platforms to encourage physical activity, healthy eating, and goal setting. By incorporating animated characters, rewards, and age-appropriate education, these apps improve adherence and behavior change in ways traditional programs often fail to.
DTx for pediatrics must be designed with safety, usability, and ethical concerns in mind. Parental controls, secure data management, and age-appropriate content are essential. Regulatory pathways are evolving to reflect the unique challenges of pediatric digital health.
As adoption grows, DTx will become a vital complement to pediatric care—delivering clinically validated therapies in engaging, child-centric formats.